Clinical Trials

27 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT04795661 2026-01-07

IMHOTEP

240 enrolled

Neoplasms

NCT04847466 2025-12-24

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

18 enrolled

Neoplasms

NCT04964960 2025-10-31

Pembro+Chemo in Brain Mets

Phase 2 Terminated

3 enrolled 7 charts

CNSThoracic

Brain Neoplasms, Lung Neoplasms, Neoplasms

NCT03505320 2025-10-20

ILUSTRO

143 enrolled

Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT05064280 2025-10-09

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Phase 2 Recruiting

104 enrolled

CNS

Brain Neoplasms, Neoplasms

NCT05271604 2025-09-26

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

42 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT05304546 2025-07-22

MK3475-C01

1 enrolled

Dermatologic

Melanoma, Neoplasms

NCT04830124 2025-06-10

ARTISTRY-6

Phase 2 Terminated

173 enrolled

Dermatologic

Melanoma, Neoplasms

NCT04976634 2025-04-06

MK-6482-016

730 enrolled

Neoplasms

NCT03632941 2025-03-12

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer

8 enrolled 13 charts

Breast

Breast Neoplasms, Neoplasms

NCT04510636 2024-03-22

Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Phase 2 Recruiting

37 enrolled

Neoplasms, Recurrence

NCT03349450 2023-11-02

SPiReL

25 enrolled

LymphoidSarcoma

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT03308942 2023-10-16

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

53 enrolled 35 charts

GastrointestinalGynecologic

Neoplasms

NCT02858921 2023-08-30

Neo Trio

Phase 2 Unknown

60 enrolled

Dermatologic

Melanoma, Neoplasms

NCT04258683 2023-08-29

A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

Phase 2 Withdrawn

Plasma cell

Cardiovascular Diseases, Hematologic Diseases, Immune System Diseases, Multiple Myeloma, Neoplasms

NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Phase 2 Recruiting

24 enrolled

Carcinoma, Ovarian Epithelial, Genital Neoplasms, Female, Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Stomach Neoplasms, Urogenital Neoplasms

NCT02798406 2021-07-15

CAPTIVE

49 enrolled

CNSSarcoma

Brain Neoplasms, Disease, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue, Nervous System Diseases, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Gliosarcoma

NCT03832673 2021-02-26

PECULIAR

Phase 2 Withdrawn

Neoplasms

NCT02981524 2021-02-10

Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer